Actinium Advances HER3-Targeted Radiotherapy In Phase 1 Prostate Cancer Study

Actinium Pharmaceuticals (ATNM) has started patient enrollment in its RADIANZ imaging trial. The study will evaluate ⁸⁹Zr-Barecetamab-DFO using PET imaging to guide development of ATNM-400 in solid tumors. It includes patients with non-small cell lung, breast, colorectal, pancreatic, and ovarian cancers. The trial follows initial results from a Phase 1 study in prostate cancer, showing no dose-limiting toxicities.

Actinium Pharmaceuticals (ATNM) has begun enrolling patients in the RADIANZ clinical trial for ATNM-400, a HER3-targeting radiotherapy. The study aims to expand ATNM-400's potential beyond prostate cancer to other solid tumors. Initial data in prostate cancer showed tumor uptake and no dose-limiting toxicities. The company plans to present additional breast cancer data at the San Antonio Breast Cancer Symposium.

Actinium Pharmaceuticals (ATNM) announced three abstracts for ASH 2026, highlighting Iomab-ACT's potential in CAR T-cell therapy and sickle cell disease. The studies explore Iomab-ACT as a conditioning agent before cellular therapies, reducing reliance on chemotherapy. According to the company, the results support Iomab-ACT's development as a universal targeted conditioning regimen.

Actinium Pharmaceuticals (ATNM) announced long-term safety results of Actimab-A combined with CLAG-M for relapsed/refractory AML at ASH 2026. The study showed potential for bone marrow recovery and addressed kidney/liver toxicities. Prior data showed 1- and 2-year survival rates of 59% and 32% in venetoclax-failed patients, and 51% and 19% in TP53-mutated AML patients. Actinium aims to develop Actimab-A as a mutation-agnostic AML treatment.

Actinium Pharmaceuticals (ATNM) announced its first-in-human Phase 1 study of ATNM-400, a HER3-targeted radiotherapy for metastatic castration-resistant prostate cancer, will be presented at ESMO 2026. The study evaluates safety, dosing, and antitumor activity, with potential to address treatment resistance across multiple solid tumors. ATNM-400 targets HER3, distinct from PSMA, and is designed to deliver Actinium-225 to tumor cells.

Biohaven (BHVN) +31% after FDA accepted resubmitted drug application for spinocerebellar ataxia. Korro Bio (KRRO) +25% on positive preclinical results for AATD treatment. Actinium (ATNM) +18% with initial Phase 1 data for prostate cancer radiotherapy. Vicore (VCRE) +16% after passing IPF trial futility analysis.